|
000
| 01791nam 2200325zi 4500 |
|---|
| 001 | 9.932422 |
|---|
| 003 | CaOODSP |
|---|
| 005 | 20240229150803 |
|---|
| 006 | m o d f |
|---|
| 007 | cr |n||||||||| |
|---|
| 008 | 240112e202005 onca ob f000 0 eng d |
|---|
| 040 | |aCaOODSP|beng|erda|cCaOODSP |
|---|
| 043 | |an-cn--- |
|---|
| 086 | 1 |aH14-526/2020E-PDF |
|---|
| 245 | 00|aEvaluation of the Thalidomide Survivors Contribution Program 2015 to 2019 / |cprepared by Office of Audit and Evaluation, Health Canada and the Public Health Agency of Canada. |
|---|
| 264 | 1|a[Ottawa] : |bHealth Canada and the Public Health Agency of Canada = Santé Canada et l'Agence de la santé publique du Canada, |cMay 2020. |
|---|
| 300 | |a1 online resource (iii, 10 pages) : |billustration |
|---|
| 336 | |atext|btxt|2rdacontent |
|---|
| 337 | |acomputer|bc|2rdamedia |
|---|
| 338 | |aonline resource|bcr|2rdacarrier |
|---|
| 500 | |aIssued also in French under title: Évaluation du Programme de contribution pour les survivants de la thalidomide 2015 à 2019. |
|---|
| 504 | |aIncludes bibliographical references (pages 9-10). |
|---|
| 650 | 0|aSurvivors' benefits|zCanada|xEvaluation. |
|---|
| 650 | 0|aThalidomide|xTreatment|zCanada. |
|---|
| 710 | 1 |aCanada. |bHealth Canada. |bOffice of Audit and Evaluation, |eissuing body. |
|---|
| 710 | 2 |aPublic Health Agency of Canada. |bOffice of Audit and Evaluation, |eissuing body. |
|---|
| 775 | 08|tÉvaluation du Programme de contribution pour les survivants de la thalidomide 2015 à 2019 / |w(CaOODSP)9.934746 |
|---|
| 856 | 40|qPDF|s245 KB|uhttps://publications.gc.ca/collections/collection_2024/sc-hc/H14-526-2020-eng.pdf |
|---|
| 856 | 4 |qHTML|sN/A|uhttps://www.canada.ca/en/health-canada/corporate/transparency/corporate-management-reporting/evaluation/thalidomide-survivors-contribution-program.html |
|---|